Rovelizumab Biosimilar – Anti-ITGAL, CD11a, ITGB2, CD18 mAb – Research Grade

Description of Rovelizumab Biosimilar - Anti-ITGAL, CD11a, ITGB2, CD18 mAb - Research Grade

Introduction

Rovelizumab Biosimilar, also known as Anti-ITGAL, CD11a, ITGB2, CD18 monoclonal antibody (mAb), is a research-grade antibody that targets specific proteins involved in immune response and inflammation. This biosimilar has shown promising results in preclinical studies and is currently being evaluated for its therapeutic potential in various diseases.

Structure and Mechanism of Action

Rovelizumab Biosimilar is a recombinant humanized monoclonal antibody that specifically binds to the integrin receptors ITGAL (CD11a) and ITGB2 (CD18) on the surface of immune cells. These receptors are part of the β2 integrin family and are involved in cell adhesion and migration. By binding to these receptors, Rovelizumab Biosimilar blocks their interaction with their ligands, preventing the activation and recruitment of immune cells to sites of inflammation.

In addition, Rovelizumab Biosimilar also targets CD11a and CD18, which are subunits of the lymphocyte function-associated antigen-1 (LFA-1) receptor. LFA-1 is a key player in the adhesion and migration of immune cells, and its inhibition by Rovelizumab Biosimilar can reduce the infiltration of immune cells into inflamed tissues.

Clinical Applications

Rovelizumab Biosimilar has shown promising results in preclinical studies as a potential treatment for various inflammatory and autoimmune diseases. It has been studied in animal models of rheumatoid arthritis, psoriasis, multiple sclerosis, and inflammatory bowel disease, among others.

One of the main advantages of Rovelizumab Biosimilar is its potential to target multiple pathways involved in inflammation. By blocking the interaction of immune cells with their ligands and inhibiting LFA-1 activity, Rovelizumab Biosimilar can effectively reduce the recruitment and activation of immune cells, leading to a decrease in inflammation.

In addition, Rovelizumab Biosimilar has also shown potential as an adjuvant therapy for cancer treatment. By targeting the immune cells involved in tumor growth and metastasis, Rovelizumab Biosimilar can enhance the efficacy of other anti- cancer treatments and improve patient outcomes.

Research Grade Antibody

Rovelizumab Biosimilar is currently being developed as a research-grade antibody, which means that it is intended for use in laboratory research and not for clinical use. This allows scientists to study the antibody’s mechanism of action and potential therapeutic applications in various diseases.

Future Directions

The potential of Rovelizumab Biosimilar as a therapeutic agent is currently being evaluated in clinical trials. These studies will provide valuable information on the safety and efficacy of this antibody in humans and pave the way for its potential use in the treatment of inflammatory and autoimmune diseases.

Conclusion

In summary, Rovelizumab Biosimilar is a research-grade antibody that targets specific proteins involved in immune response and inflammation. Its unique mechanism of action, targeting multiple pathways, makes it a promising candidate for the treatment of various diseases. Further research and clinical trials are needed to fully understand the potential of this antibody and its role in improving patient outcomes.